Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Assembly Biosciences (ASMB) EBITDA Margin: 2017-2025

Historic EBITDA Margin for Assembly Biosciences (ASMB) over the last 6 years, with Sep 2025 value amounting to -83.48%.

  • Assembly Biosciences' EBITDA Margin rose 5495.00% to -83.48% in Q3 2025 from the same period last year, while for Sep 2025 it was -103.47%, marking a year-over-year increase of 4016.00%. This contributed to the annual value of -141.33% for FY2024, which is 70337.00% up from last year.
  • Latest data reveals that Assembly Biosciences reported EBITDA Margin of -83.48% as of Q3 2025, which was up 21.40% from -106.21% recorded in Q2 2025.
  • Assembly Biosciences' 5-year EBITDA Margin high stood at -83.48% for Q3 2025, and its period low was -300.90% during Q3 2021.
  • In the last 3 years, Assembly Biosciences' EBITDA Margin had a median value of -134.88% in 2024 and averaged -125.59%.
  • Per our database at Business Quant, Assembly Biosciences' EBITDA Margin slumped by 29,046bps in 2021 and then surged by 6,557bps in 2025.
  • Over the past 4 years, Assembly Biosciences' EBITDA Margin (Quarterly) stood at -300.90% in 2021, then reached -150.33% in 2023, then soared by 910bps to -141.23% in 2024, then surged by 5,495bps to -83.48% in 2025.
  • Its EBITDA Margin was -83.48% in Q3 2025, compared to -106.21% in Q2 2025 and -94.07% in Q1 2025.